SIMONSEN, Anja Hviid, Bea KUIPERIJ, Omar Mukhtar Ali EL-AGNAF, Sebastian ENGELBORGHS, Sanna-Kaisa HERUKKA, Lucilla PARNETTI, Irena REKTOROVÁ, Eugeen VANMECHELEN, Elisabeth KAPAKI, Marcel VERBEEK a Brit MOLLENHAUER. The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. BIOMARKERS IN MEDICINE. LONDON: FUTURE MEDICINE LTD, 2016, roč. 10, č. 1, s. 19-34. ISSN 1752-0363. Dostupné z: https://dx.doi.org/10.2217/BMM.14.105. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1337320, author = {Simonsen, Anja Hviid and Kuiperij, Bea and ElandAgnaf, Omar Mukhtar Ali and Engelborghs, Sebastian and Herukka, SannaandKaisa and Parnetti, Lucilla and Rektorová, Irena and Vanmechelen, Eugeen and Kapaki, Elisabeth and Verbeek, Marcel and Mollenhauer, Brit}, article_location = {LONDON}, article_number = {1}, doi = {http://dx.doi.org/10.2217/BMM.14.105}, keywords = {alpha-synuclein; biomarker; CSF; diagnosis; ELISA; Parkinson's disease}, language = {eng}, issn = {1752-0363}, journal = {BIOMARKERS IN MEDICINE}, title = {The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature}, url = {http://www.futuremedicine.com/doi/10.2217/BMM.14.105}, volume = {10}, year = {2016} }
TY - JOUR ID - 1337320 AU - Simonsen, Anja Hviid - Kuiperij, Bea - El-Agnaf, Omar Mukhtar Ali - Engelborghs, Sebastian - Herukka, Sanna-Kaisa - Parnetti, Lucilla - Rektorová, Irena - Vanmechelen, Eugeen - Kapaki, Elisabeth - Verbeek, Marcel - Mollenhauer, Brit PY - 2016 TI - The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature JF - BIOMARKERS IN MEDICINE VL - 10 IS - 1 SP - 19-34 EP - 19-34 PB - FUTURE MEDICINE LTD SN - 17520363 KW - alpha-synuclein KW - biomarker KW - CSF KW - diagnosis KW - ELISA KW - Parkinson's disease UR - http://www.futuremedicine.com/doi/10.2217/BMM.14.105 L2 - http://www.futuremedicine.com/doi/10.2217/BMM.14.105 N2 - The discovery of -synuclein (-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of -syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of -syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of -syn has yielded novel insights into the variety of -syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of -syn as biomarker. We also suggest future approaches to use of CSF -syn in neurodegenerative diseases. ER -
SIMONSEN, Anja Hviid, Bea KUIPERIJ, Omar Mukhtar Ali EL-AGNAF, Sebastian ENGELBORGHS, Sanna-Kaisa HERUKKA, Lucilla PARNETTI, Irena REKTOROVÁ, Eugeen VANMECHELEN, Elisabeth KAPAKI, Marcel VERBEEK a Brit MOLLENHAUER. The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. \textit{BIOMARKERS IN MEDICINE}. LONDON: FUTURE MEDICINE LTD, 2016, roč.~10, č.~1, s.~19-34. ISSN~1752-0363. Dostupné z: https://dx.doi.org/10.2217/BMM.14.105.
|